Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3 - Concepedia

Concepedia

Publication | Closed Access

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

620

Citations

41

References

2008

Year

Dana D. Hu‐Lowe, Helen Y. Zou, Maren L. Grazzini, Max Hallin, Grant Wickman, Karin Amundson, Jeffrey H. Chen, David A. Rewolinski, Shinji Yamazaki, Michele McTigue,

Clinical Cancer Research

Abstract

The selectivity, potency for VEGFRs, and robust nonclinical activity may afford broad opportunities for axitinib to improve cancer therapy.

References

	Year	Citations

Page 1